Zylox-Tonbridge Medical Technology Croissance future
Future contrôle des critères 5/6
Zylox-Tonbridge Medical Technology is forecast to grow earnings and revenue by 69.8% and 23.8% per annum respectively. EPS is expected to grow by 69.9% per annum. Return on equity is forecast to be 6.6% in 3 years.
Informations clés
69.8%
Taux de croissance des bénéfices
69.9%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 39.2% |
| Taux de croissance des recettes | 23.8% |
| Rendement futur des capitaux propres | 6.6% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 02 Sep 2024 |
Mises à jour récentes de la croissance future
Recent updates
Market Participants Recognise Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Revenues Pushing Shares 27% Higher
Oct 02
Solid Earnings Reflect Zylox-Tonbridge Medical Technology's (HKG:2190) Strength As A Business
Sep 27Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Does This Valuation Of Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Imply Investors Are Overpaying?
Sep 21There's Reason For Concern Over Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Price
Aug 03We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jun 30Is Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Trading At A 45% Discount?
Mar 08We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jan 19Here's Why We're Not Too Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Jul 06We're Hopeful That Zylox-Tonbridge Medical Technology (HKG:2190) Will Use Its Cash Wisely
Jan 27Here's Why We're Not At All Concerned With Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Oct 05Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 1,486 | 309 | 29 | 327 | 4 |
| 12/31/2025 | 1,098 | 188 | -64 | 177 | 4 |
| 12/31/2024 | 781 | 101 | -146 | 25 | 4 |
| 6/30/2024 | 664 | 26 | 23 | 221 | N/A |
| 3/31/2024 | 596 | -27 | -35 | 160 | N/A |
| 12/31/2023 | 528 | -79 | -92 | 98 | N/A |
| 9/30/2023 | 470 | -101 | -171 | 19 | N/A |
| 6/30/2023 | 411 | -124 | -250 | -60 | N/A |
| 3/31/2023 | 373 | -119 | -244 | -76 | N/A |
| 12/31/2022 | 334 | -114 | -237 | -91 | N/A |
| 9/30/2022 | 297 | -135 | -242 | -107 | N/A |
| 6/30/2022 | 259 | -155 | -247 | -122 | N/A |
| 3/31/2022 | 219 | -178 | -227 | -119 | N/A |
| 12/31/2021 | 178 | -200 | -206 | -116 | N/A |
| 9/30/2021 | 137 | -168 | -186 | -107 | N/A |
| 6/30/2021 | 97 | -135 | -166 | -98 | N/A |
| 3/31/2021 | 62 | -118 | -147 | -90 | N/A |
| 12/31/2020 | 28 | -100 | -127 | -82 | N/A |
| 12/31/2019 | 5 | -67 | -95 | -53 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 2190's forecast earnings growth (69.8% per year) is above the savings rate (2.3%).
Bénéfices vs marché: 2190's earnings (69.8% per year) are forecast to grow faster than the Hong Kong market (11.5% per year).
Croissance élevée des bénéfices: 2190's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 2190's revenue (23.8% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
Croissance élevée des revenus: 2190's revenue (23.8% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 2190's Return on Equity is forecast to be low in 3 years time (6.6%).